The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study
Objectives: To evaluate the clinical features of pediatric non-infectious uveitis (NIU) patients treated with adalimumab (ADA) and the efficacy of ADA in patients unresponsive to conventional immunosuppressive therapy. Materials and Methods: The records of 91 NIU patients aged ≤16 years who receive...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2024-12-01
|
| Series: | Türk Oftalmoloji Dergisi |
| Subjects: | |
| Online Access: | https://www.oftalmoloji.org/articles/the-efficacy-of-adalimumab-treatment-in-pediatric-non-infectious-uveitis-a-retrospective-cohort-study/doi/tjo.galenos.2024.70371 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556472496914432 |
|---|---|
| author | Kübra Özdemir Yalçınsoy Osman Özen Yasemin Özdamar Erol Pınar Çakar Özdal |
| author_facet | Kübra Özdemir Yalçınsoy Osman Özen Yasemin Özdamar Erol Pınar Çakar Özdal |
| author_sort | Kübra Özdemir Yalçınsoy |
| collection | DOAJ |
| description | Objectives: To evaluate the clinical features of pediatric non-infectious uveitis (NIU) patients treated with adalimumab (ADA) and the efficacy of ADA in patients unresponsive to conventional immunosuppressive therapy.
Materials and Methods: The records of 91 NIU patients aged ≤16 years who received ADA therapy were evaluated retrospectively. The patients’ demographic and clinical characteristics and treatment approaches were recorded. The efficacy of ADA in patients treated for at least 1 year after failure of conventional immunosuppressive treatment was evaluated by comparing the best corrected visual acuity (BCVA), severity of intraocular inflammation, uveitis flare-ups, topical and systemic corticosteroid (CS) use, and central macular thickness (CMT) values before and after ADA treatment.
Results: The study included 103 eyes of 53 patients, of whom 29 (54.7%) were female. The mean age at presentation was 8.2±3.4 (range: 3-16) years. The mean follow-up period was 41.6±28.2 (range: 18-120) months. Twenty-six patients (49.0%) had anterior uveitis, 22 (41.5%) had intermediate uveitis, and 5 (9.4%) had panuveitis. The mean duration of ADA treatment was 23.0±13.7 (range: 12-60) months. Uveitis flare-ups developed in only 13 patients (24.5%) while on ADA treatment. When pre- and post-treatment periods were compared, the mean number of uveitis flare-ups, intraocular inflammation severity, mean dose of topical and systemic CS, and mean CMT values were significantly lower in the post-treatment period (p<0.05). The mean BCVA was significantly improved after 6 and 12 months of ADA treatment compared to the pre-treatment visual acuity (p<0.05).
Conclusion: ADA effectively controlled intraocular inflammation, reducing the need for systemic and topical CS and improving visual outcomes in pediatric NIU. |
| format | Article |
| id | doaj-art-08ca458fb65c46ddaf3b6cb94238d6b3 |
| institution | Kabale University |
| issn | 1300-0659 2147-2661 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türk Oftalmoloji Dergisi |
| spelling | doaj-art-08ca458fb65c46ddaf3b6cb94238d6b32025-01-07T08:20:00ZengGalenos YayineviTürk Oftalmoloji Dergisi1300-06592147-26612024-12-0154633734310.4274/tjo.galenos.2024.70371The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort StudyKübra Özdemir Yalçınsoy0https://orcid.org/0000-0002-3352-9547Osman Özen1https://orcid.org/0000-0003-1685-6885Yasemin Özdamar Erol2https://orcid.org/0000-0002-0406-8921Pınar Çakar Özdal3https://orcid.org/0000-0002-5714-7172University of Health Sciences Türkiye, Ulucanlar Eye Training and Research Hospital, Clinic of Ophthalmology, Ankara, TürkiyeKastamonu Training and Research Hospital, Clinic of Ophthalmology, Kastamonu, TürkiyeUniversity of Health Sciences Türkiye, Ankara Etlik City Hospital, Clinic of Ophthalmology, Ankara, TürkiyeUvea Academy Eye Clinic, Ankara, TürkiyeObjectives: To evaluate the clinical features of pediatric non-infectious uveitis (NIU) patients treated with adalimumab (ADA) and the efficacy of ADA in patients unresponsive to conventional immunosuppressive therapy. Materials and Methods: The records of 91 NIU patients aged ≤16 years who received ADA therapy were evaluated retrospectively. The patients’ demographic and clinical characteristics and treatment approaches were recorded. The efficacy of ADA in patients treated for at least 1 year after failure of conventional immunosuppressive treatment was evaluated by comparing the best corrected visual acuity (BCVA), severity of intraocular inflammation, uveitis flare-ups, topical and systemic corticosteroid (CS) use, and central macular thickness (CMT) values before and after ADA treatment. Results: The study included 103 eyes of 53 patients, of whom 29 (54.7%) were female. The mean age at presentation was 8.2±3.4 (range: 3-16) years. The mean follow-up period was 41.6±28.2 (range: 18-120) months. Twenty-six patients (49.0%) had anterior uveitis, 22 (41.5%) had intermediate uveitis, and 5 (9.4%) had panuveitis. The mean duration of ADA treatment was 23.0±13.7 (range: 12-60) months. Uveitis flare-ups developed in only 13 patients (24.5%) while on ADA treatment. When pre- and post-treatment periods were compared, the mean number of uveitis flare-ups, intraocular inflammation severity, mean dose of topical and systemic CS, and mean CMT values were significantly lower in the post-treatment period (p<0.05). The mean BCVA was significantly improved after 6 and 12 months of ADA treatment compared to the pre-treatment visual acuity (p<0.05). Conclusion: ADA effectively controlled intraocular inflammation, reducing the need for systemic and topical CS and improving visual outcomes in pediatric NIU.https://www.oftalmoloji.org/articles/the-efficacy-of-adalimumab-treatment-in-pediatric-non-infectious-uveitis-a-retrospective-cohort-study/doi/tjo.galenos.2024.70371pediatric uveitisnon-infectious uveitistreatmentadalimumabtumor necrosis factor alpha |
| spellingShingle | Kübra Özdemir Yalçınsoy Osman Özen Yasemin Özdamar Erol Pınar Çakar Özdal The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study Türk Oftalmoloji Dergisi pediatric uveitis non-infectious uveitis treatment adalimumab tumor necrosis factor alpha |
| title | The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study |
| title_full | The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study |
| title_fullStr | The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study |
| title_full_unstemmed | The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study |
| title_short | The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study |
| title_sort | efficacy of adalimumab treatment in pediatric non infectious uveitis a retrospective cohort study |
| topic | pediatric uveitis non-infectious uveitis treatment adalimumab tumor necrosis factor alpha |
| url | https://www.oftalmoloji.org/articles/the-efficacy-of-adalimumab-treatment-in-pediatric-non-infectious-uveitis-a-retrospective-cohort-study/doi/tjo.galenos.2024.70371 |
| work_keys_str_mv | AT kubraozdemiryalcınsoy theefficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT osmanozen theefficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT yaseminozdamarerol theefficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT pınarcakarozdal theefficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT kubraozdemiryalcınsoy efficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT osmanozen efficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT yaseminozdamarerol efficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy AT pınarcakarozdal efficacyofadalimumabtreatmentinpediatricnoninfectiousuveitisaretrospectivecohortstudy |